$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz

$celz Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000147793222005931 Filed on August 12, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$55.00K	$0.00	$15.00K
YoY Change	450.0%	-100.0%
Cost Of Revenue	$16.00K	$0.00	$6.791K
YoY Change	300.0%	-100.0%
Gross Profit	$39.00K	$0.00	$8.209K
YoY Change	550.0%	-100.0%
Gross Profit Margin	70.91%		54.73%
Selling, General & Admin	$805.5K	$1.108M	$1.130M
YoY Change	6.37%	122.43%	302.27%
% of Gross Profit	2065.28%		13766.07%
Research & Development	$230.9K	$659.7K	$10.00K
YoY Change	290.23%
% of Gross Profit	592.15%		121.82%
Depreciation & Amortization	$23.02K	$23.02K	$23.02K
YoY Change	0.0%	0.0%	0.0%
% of Gross Profit	59.03%		280.42%
Operating Expenses	$1.059M	$1.791M	$1.163M
YoY Change	26.21%	243.56%	282.67%
Operating Profit	-$1.020M	-$1.791M	-$1.155M
YoY Change	22.44%	247.23%	279.97%
Interest Expense	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
% of Operating Profit
Other Income/Expense, Net	$38.08K	$0.00	$0.00
YoY Change	-103.77%	-100.0%	-100.0%
Pretax Income	-$982.3K	-$1.791M	-$1.155M
YoY Change	-46.72%	-38.35%	-104.15%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$982.3K	-$1.791M	-$1.155M
YoY Change	-46.72%	-38.35%	-104.15%
Net Earnings / Revenue	-1786.07%		-7699.13%
Basic Earnings Per Share	-$0.07	-$0.20	-$0.18
Diluted Earnings Per Share	-$0.07	-$0.20	-$0.18
COMMON SHARES
Basic Shares Outstanding	14.07M shares	9.011M shares	6.454M shares
Diluted Shares Outstanding	14.07M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.97M	$22.86M	$9.147M
YoY Change	613.61%	14316.84%	3224.6%
Cash & Equivalents	$16.97M	$22.86M	$9.147M
Short-Term Investments
Other Short-Term Assets	$5.021M	$64.96K	$64.96K
YoY Change
Inventory	$15.89K	$20.63K	$14.15K
Prepaid Expenses
Receivables	$0.00	$0.00	$0.00
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$22.01M	$22.95M	$9.226M
YoY Change	753.64%	14370.99%	3253.36%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.280K	$3.280K	$3.281K
YoY Change	0.0%
Total Long-Term Assets	$461.9K	$484.9K	$507.9K
YoY Change	-16.62%	-15.48%	-14.88%
TOTAL ASSETS
Total Short-Term Assets	$22.01M	$22.95M	$9.226M
Total Long-Term Assets	$461.9K	$484.9K	$507.9K
Total Assets	$22.47M	$23.43M	$9.734M
YoY Change	617.39%	3100.04%	1016.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$327.8K	$310.7K	$335.7K
YoY Change	-27.87%	-14.89%	-5.71%
Accrued Expenses	$54.92K	$64.92K	$29.92K
YoY Change	83.56%	-9.17%	-55.84%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$397.0K	$389.8K	$379.8K
YoY Change	-88.64%	-73.06%	-88.54%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$397.0K	$389.8K	$379.8K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$397.0K	$389.8K	$379.8K
YoY Change	-88.64%	-73.06%	-88.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$47.60M	-$46.61M	-$44.82M
YoY Change	22.66%	26.12%
Common Stock	$14.08K	$13.96K	$6.521K
YoY Change	472.7%	-98.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$22.07M	$23.04M	$9.354M
YoY Change
Total Liabilities & Shareholders Equity	$22.47M	$23.43M	$9.734M
YoY Change	617.39%	3100.04%	1016.44%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$982.3K	-$1.791M	-$1.155M
YoY Change	-46.72%	-38.35%	-104.15%
Depreciation, Depletion And Amortization	$23.02K	$23.02K	$23.02K
YoY Change	0.0%	0.0%	0.0%
Cash From Operating Activities	-$873.3K	-$1.756M	-$1.577M
YoY Change	123.47%	690.29%	257.15%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$5.021M	$0.00	$0.00
YoY Change	2410.66%
Cash From Investing Activities	-$5.021M	$0.00	$0.00
YoY Change	2410.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.00	15.47M	$0.00
YoY Change	-100.0%	14553.11%	-100.0%
NET CHANGE
Cash From Operating Activities	-873.3K	-1.756M	-$1.577M
Cash From Investing Activities	-5.021M	0.000	$0.00
Cash From Financing Activities	10.00	15.47M	$0.00
Net Change In Cash	-5.895M	13.72M	-$1.577M
YoY Change	-365.6%	-11868.92%	-990.29%
FREE CASH FLOW
Cash From Operating Activities	-$873.3K	-$1.756M	-$1.577M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2021Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
	dei	Entity Central Index Key EntityCentralIndexKey	0001187953
	celz	Amortization Expenses AmortizationExpenses	4986	usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-53500
	dei	Entity Registrant Name EntityRegistrantName	CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-0622284
	dei	Entity Address Address Line1 EntityAddressAddressLine1	211 E Osborn Road
	dei	Entity Address City Or Town EntityAddressCityOrTown	Phoenix
	dei	Entity Address State Or Province EntityAddressStateOrProvince	AZ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	85012
	dei	City Area Code CityAreaCode	480
	dei	Local Phone Number LocalPhoneNumber	399-2822
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	14070279	shares
CY2022Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	0	usd
CY2022Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.001
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.25
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.25
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9011248	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2320084	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7739696	shares
CY2022Q2	celz	Weighted Average Number Of Shares Outstanding Diluted WeightedAverageNumberOfSharesOutstandingDiluted	9011248	shares
CY2021Q2	celz	Weighted Average Number Of Shares Outstanding Diluted WeightedAverageNumberOfSharesOutstandingDiluted	2320084	shares
	celz	Weighted Average Number Of Shares Outstanding Diluted WeightedAverageNumberOfSharesOutstandingDiluted	7739696	shares
	celz	Weighted Average Number Of Shares Outstanding Diluted WeightedAverageNumberOfSharesOutstandingDiluted	2328927	shares
	us-gaap	Profit Loss ProfitLoss	2946013	usd
	us-gaap	Profit Loss ProfitLoss	-24930837	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	50422	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	211768	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	46042	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	46042	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	451614	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-26224593	usd
	us-gaap	Interest Expense InterestExpense	570414	usd
	celz	Increase In Principal And Accrued Interest Balances Due To Penalty Provision IncreaseInPrincipalAndAccruedInterestBalancesDueToPenaltyProvision	0	usd
	celz	Increase In Principal And Accrued Interest Balances Due To Penalty Provision IncreaseInPrincipalAndAccruedInterestBalancesDueToPenaltyProvision	-93821	usd
	celz	Gain On Extinguishment Of Convertible Notes GainOnExtinguishmentOfConvertibleNotes	96444	usd
	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	0	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1791144	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-2905182	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2946013	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	40535	usd
	celz	Change In Fair Value Of Derivatives Liabilities ChangeInFairValueOfDerivativesLiabilities	26224593	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	0	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2389340	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	0	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1791144	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2905182	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2946013	usd
CY2022Q2	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	0	usd
CY2021Q2	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	0	usd
	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	96444	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2485	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9759	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	64960	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-451181	usd
	us-gaap	Increase Decrease In Payables To Customers IncreaseDecreaseInPayablesToCustomers	0	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-2442573	usd
CY2021Q2	celz	Common Stock Issued For Related Party Management Liabilities Amount CommonStockIssuedForRelatedPartyManagementLiabilitiesAmount	0	usd
	us-gaap	Increase Decrease In Payables To Customers IncreaseDecreaseInPayablesToCustomers	-116200	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3332429	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	341788	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2021Q2	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	4100498	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	15471775	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	445	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	100000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	134640	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	462000	usd
CY2020Q3	celz	Company Paid CompanyPaid	40000	usd
CY2020Q3	celz	Obligation Of The Initial Payment ObligationOfTheInitialPayment	300000	usd
	celz	Dividends On Preferred Stock DividendsOnPreferredStock	-20752	usd
	celz	Cashless Exercise Of Warrants Amount CashlessExerciseOfWarrantsAmount	0	usd
	celz	Stock Based Compensation StockBasedCompensation	211768	usd
	us-gaap	Net Income Loss NetIncomeLoss	24930837	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-714453	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	226500	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	198907	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15472220	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	724233	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	12139791	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	60576	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10723870	usd
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	98012	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22863661	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	158588	usd
	celz	Conversion Of Notes Payable Accrued Interest And Derivative Liabilities Into Common Stock ConversionOfNotesPayableAccruedInterestAndDerivativeLiabilitiesIntoCommonStock	0	usd
	celz	Conversion Of Notes Payable Accrued Interest And Derivative Liabilities Into Common Stock ConversionOfNotesPayableAccruedInterestAndDerivativeLiabilitiesIntoCommonStock	13454704	usd
	celz	Conversion Of Management Fees And Patent Liability Into Common Stock ConversionOfManagementFeesAndPatentLiabilityIntoCommonStock	250000	usd
	celz	Discounts On Convertible Notes Payable Due To Derivative Liabilities DiscountsOnConvertibleNotesPayableDueToDerivativeLiabilities	0	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	10217740	usd
	celz	Issuance Of Common Stock And Accompanying Warrants Net Of Issuance Costs Amount IssuanceOfCommonStockAndAccompanyingWarrantsNetOfIssuanceCostsAmount	15471775	usd
	celz	Common Stock Issued For Related Party Patent Liabilities Amount CommonStockIssuedForRelatedPartyPatentLiabilitiesAmount	250000	usd
	celz	Common Stock Issued For Warrant Exercise Amount CommonStockIssuedForWarrantExerciseAmount	445	usd
	celz	Stock Based Compensation StockBasedCompensation	50422	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2946013	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	23044369	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	9354231	usd
CY2022Q2	celz	Issuance Of Common Stock And Accompanying Warrants Net Of Issuance Costs Amount IssuanceOfCommonStockAndAccompanyingWarrantsNetOfIssuanceCostsAmount	15471775	usd
CY2022Q2	celz	Common Stock Issued For Warrant Exercise Amount CommonStockIssuedForWarrantExerciseAmount	445	usd
CY2022Q2	celz	Stock Based Compensation StockBasedCompensation	9062	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1791144	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	23044369	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-39803010	usd
	celz	Proceeds From Sales Of Preferred Stock Amount ProceedsFromSalesOfPreferredStockAmount	462000	usd
	celz	Common Stock Issued For Related Party Management Liabilities Amount CommonStockIssuedForRelatedPartyManagementLiabilitiesAmount	50000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1229351	usd
	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	12225353	usd
CY2021Q2	celz	Dividends On Preferred Stock DividendsOnPreferredStock	-20752	usd
CY2021Q2	celz	Cashless Exercise Of Warrants Amount CashlessExerciseOfWarrantsAmount	0	usd
CY2021Q2	celz	Stock Based Compensation StockBasedCompensation	211768	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-2905182	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-714453	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Use of Estimates</em></strong> – The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2020Q3	celz	Common Stock Issue Share CommonStockIssueShare	84656	shares
CY2021Q1	celz	Company Paid CompanyPaid	50000	usd
CY2016Q1	celz	No Of Share Exchange NoOfShareExchange	431111	shares
CY2016Q1	celz	Restricted Common Stock RestrictedCommonStock	100000	usd
	us-gaap	Interest Expense Other InterestExpenseOther	118000	usd
	celz	Expiration Period Of Finite Lived Intangible Assets ExpirationPeriodOfFiniteLivedIntangibleAssets	2025
	celz	Amortization Expenses AmortizationExpenses	4986	usd
CY2022Q2	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	36000	usd
	celz	Expected Amount Of Amortization ExpectedAmountOfAmortization	9972	usd
CY2019Q4	celz	Cash Payment In Intial Payment CashPaymentInIntialPayment	50000	usd
CY2019Q4	celz	Common Stock Issue Share CommonStockIssueShare	6667	shares
CY2021Q1	celz	Company Paid CompanyPaid	50000	usd
CY2021Q1	celz	Obligation Of The Initial Payment ObligationOfTheInitialPayment	300000	usd
CY2022Q2	us-gaap	Time Deposits At Or Above Fdic Insurance Limit TimeDepositsAtOrAboveFDICInsuranceLimit	250000	usd
	celz	Weighted Average Common Shares Outstanding Used In Calculating Basic Earnings Per Share WeightedAverageCommonSharesOutstandingUsedInCalculatingBasicEarningsPerShare	2242318	shares
	celz	Effect Of Series B And C Preferred Stock Share EffectOfSeriesBAndCPreferredStockShare	24000	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	35873	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	22115	shares
	celz	Incremental Common Shares Attributable To Dilutive Effect Of Convertible Related Party Management Fee And Patent Liabilities IncrementalCommonSharesAttributableToDilutiveEffectOfConvertibleRelatedPartyManagementFeeAndPatentLiabilities	4623	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2328929	shares
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	24930837	usd
	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	117649	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	25048486	usd
	celz	Debt Conversion Converrted Instrument Shares Issued DebtConversionConverrtedInstrumentSharesIssued	37870	shares
	celz	Common Stock Issued For Cashless Warrant Exercise Shares CommonStockIssuedForCashlessWarrantExerciseShares	43167	shares
CY2021Q1	celz	Common Stock Issue Share CommonStockIssueShare	133	shares
CY2021Q1	celz	Obligation Of The Initial Payment ObligationOfTheInitialPayment	300000	usd
CY2021Q1	celz	Common Stock Issue Share CommonStockIssueShare	89286	shares
CY2020Q4	celz	License Fees LicenseFees	250000	usd
CY2020Q4	celz	License Agreement Description LicenseAgreementDescription	(the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement
CY2020Q4	celz	License Agreement Description Final LicenseAgreementDescriptionFinal	Within thirty (30) days of the end of each calendar quarter during the term of this Agreement, Licensee will pay Licensor five percent (5%) of the Net Income of ImmCelz™
CY2021Q4	celz	Licensing Agreements Beginning Balance LicensingAgreementsBeginningBalance	760000	usd
CY2021Q4	celz	Accumulated Amortization Beginning Balance AccumulatedAmortizationBeginningBalance	-232321	usd
	celz	Accumulated Amortization Addition Of New Assets AccumulatedAmortizationAdditionOfNewAssets	0	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	0	usd
	celz	Accumulated Amortization AccumulatedAmortization	-46042	usd
CY2022Q2	celz	Licensing Agreementsendingbalance LicensingAgreementsendingbalance	760000	usd
CY2022Q2	celz	Accumulated Amortization Ending Balance AccumulatedAmortizationEndingBalance	-278363	usd
CY2021Q2	celz	Proceeds From Chairman ProceedsFromChairman	50000	usd
CY2021Q2	celz	Proceeds From Director ProceedsFromDirector	150000	usd
CY2021Q3	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.05	pure
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	451614	usd
CY2021Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	120185	usd
	celz	Debt Conversion Shares Issued DebtConversionSharesIssued	772099	shares
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	1229351	usd
CY2021Q2	celz	Initial Derivative Liabilities InitialDerivativeLiabilities	817791	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P1Y
CY2021Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	683151	usd
	celz	Gain Loss Related To Change In Fair Market Value Of Derivative Liabilities GainLossRelatedToChangeInFairMarketValueOfDerivativeLiabilities	2251446	usd
	celz	Gain Loss Related To Change In Fair Market Value Of Derivative Liabilities GainLossRelatedToChangeInFairMarketValueOfDerivativeLiabilities	262224593	usd
CY2021Q2	celz	Share Price On Reveluation SharePriceOnReveluation	17.50
CY2021Q2	celz	Derivative Liabilities Fair Value DerivativeLiabilitiesFairValue	12225353	usd
	celz	Annual Dividend Yield AnnualDividendYield	0	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0081	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9295	pure
CY2022Q2	us-gaap	Share Price SharePrice	1.69
CY2022Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2991669	shares
CY2022Q2	celz	Purchase Of Warrants Shares PurchaseOfWarrantsShares	4563887	shares
CY2022Q2	celz	Purchase Of Pre Funded Warrant And Related Common Warrant PurchaseOfPreFundedWarrantAndRelatedCommonWarrant	15111112	shares
CY2022Q2	celz	Combined Offering Price Of Pre Funded Warrant And Related Common Warrant CombinedOfferingPriceOfPreFundedWarrantAndRelatedCommonWarrant	2.25
CY2022Q2	celz	Description Of Amendment DescriptionOfAmendment	pursuant to a Securities Purchase Agreement between the Company and the Purchasers dated as of April 28, 2022 (the “Purchase Agreement”), resulting in gross proceeds to the Company of approximately $17,000,000. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder
	celz	Common Warrants Term CommonWarrantsTerm	five-year
	celz	Common Warrants Exercise Price CommonWarrantsExercisePrice	2.00
	celz	Pre Funded Warrants Exercise Price PreFundedWarrantsExercisePrice	0.0001
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	2485	usd
	celz	Conversion Of Management Fees And Patent Liability Into Common Stock ConversionOfManagementFeesAndPatentLiabilityIntoCommonStock	50000	usd
	celz	Discounts On Convertible Notes Payable Due To Derivative Liabilities DiscountsOnConvertibleNotesPayableDueToDerivativeLiabilities	134640	usd

Files In Submission

Name	View Source	Status
0001477932-22-005931-index-headers.html	Edgar Link	pending
0001477932-22-005931-index.html	Edgar Link	pending
0001477932-22-005931.txt	Edgar Link	pending
0001477932-22-005931-xbrl.zip	Edgar Link	pending
celz-20220630.xsd	Edgar Link	pending
celz_10q.htm	Edgar Link	pending
celz_10qimg1.jpg	Edgar Link	pending
celz_ex311.htm	Edgar Link	pending
celz_ex312.htm	Edgar Link	pending
celz_ex321.htm	Edgar Link	pending
celz_ex322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
celz-20220630_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
celz-20220630_pre.xml	Edgar Link	unprocessable
celz-20220630_cal.xml	Edgar Link	unprocessable
celz_10q_htm.xml	Edgar Link	completed
celz-20220630_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz

2022 Q3 Form 10-Q Financial Statement

#000147793222005931 Filed on August 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz

2022 Q3 Form 10-Q Financial Statement

#000147793222005931 Filed on August 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz